Literature DB >> 2329508

[Tyr0]-calcitonin gene-related peptide 28-37 (rat) as a putative antagonist of calcitonin gene-related peptide responses on opossum internal anal sphincter smooth muscle.

S Chakder1, S Rattan.   

Abstract

The effects of calcitonin gene-related peptide (CGRP) I(alpha) (human), CGRP II(beta) (human), CGRP (rat), and [Tyr0]-CGRP (rat) on the resting tone of opossum internal anal sphincter (IAS) were studied. Different CGRPs identified above produced a concentration-dependent fall in the resting tension of the IAS. CGRP II (human) was most potent, while [Tyr0]-CGRP (rat) was the least. The fall in IAS tension caused by CGRP II (human) was not modified by the neurotoxin tetrodotoxin, beta adrenoceptor antagonist propranolol and prostaglandin synthesis inhibitor indomethacin. In contrast to the other CGRP analogs, [Tyr0]-CGRP 28-37 (rat) produced no significant effects on the resting tension of the IAS. However, the fragment caused significant rightward shifts in the concentration-effect curves of different CGRP analogs examined on the IAS. [Tyr0]-CGRP 28-37 (rat) was found to be almost equipotent in antagonizing the inhibitory effects of CGRP (rat) and [Tyr0]-CGRP (rat), but was approximately 12 and 4 times more potent in antagonizing the responses of CGRP I (human) and CGRP II (human), respectively, as compared to that of CGRP (rat) and [Tyr0]-CGRP (rat). Calcitonin, on the other hand, caused a rise in the IAS tension by its action directly at the smooth muscle and this was not modified by [Tyr0]-CGRP 28-37. Thus, we conclude that: 1) CGRP causes a fall in the resting tension of IAS by its action directly at the smooth muscle; 2) [Tyr0]-CGRP 28-37 (rat) may serve as an antagonist of CGRP responses and 3) CGRP and calcitonin produce opposite actions on the resting IAS tension by the activation of their own receptors at the smooth muscle cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2329508

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins.

Authors:  Heather E Moad; Augen A Pioszak
Journal:  Protein Sci       Date:  2013-10-19       Impact factor: 6.725

2.  CGRP(2) receptor in the internal anal sphincter of the rat: implications for CGRP receptor classification.

Authors:  F M Wisskirchen; I Marshall
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Multiple receptors for calcitonin gene-related peptide and amylin on guinea-pig ileum and vas deferens.

Authors:  A E Tomlinson; D R Poyner
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Regional haemodynamic effects of prolonged infusions of human alpha-calcitonin gene-related peptide in conscious, Long Evans rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett; R Foulkes; B Hughes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

5.  Electrophysiological effects of calcitonin gene-related peptide in bull-frog and guinea-pig atrial myocytes.

Authors:  K Ono; W R Giles
Journal:  J Physiol       Date:  1991-05       Impact factor: 5.182

6.  Effects of calcitonin gene-related peptide receptor antagonists on renal actions of adrenomedullin.

Authors:  A M Elhawary; J Poon; C C Pang
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

7.  Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes.

Authors:  D R Poyner; D P Andrew; D Brown; C Bose; M R Hanley
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

8.  Downregulation of thromboxane A2 and angiotensin II type 1 receptors associated with aging-related decrease in internal anal sphincter tone.

Authors:  Ipsita Mohanty; Jagmohan Singh; Satish Rattan
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.